Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of “Buy” from Analysts

Maplight Therapeutics, Inc. (NASDAQ:MPLT) has received an average rating of “Buy” from the five research firms that are presently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $31.00.

Several brokerages recently issued reports on MPLT. Leerink Partners began coverage on shares of Maplight Therapeutics in a research note on Friday. They set an “outperform” rating and a $30.00 price objective for the company. Leerink Partnrs upgraded Maplight Therapeutics to a “strong-buy” rating in a report on Friday. Wall Street Zen lowered Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Morgan Stanley began coverage on Maplight Therapeutics in a research report on Friday. They set an “overweight” rating and a $34.00 price objective on the stock. Finally, Jefferies Financial Group initiated coverage on Maplight Therapeutics in a report on Friday. They issued a “buy” rating and a $32.00 target price for the company.

Maplight Therapeutics Stock Up 5.3%

Shares of Maplight Therapeutics stock traded up $0.70 during trading hours on Friday, reaching $13.99. 264,746 shares of the company’s stock were exchanged, compared to its average volume of 422,979. Maplight Therapeutics has a 1 year low of $13.20 and a 1 year high of $20.86.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.